Category Regulatory

ImmunityBio Shares ISPOR 2026 Survey on Bladder Preservation Preference in UK NMIBC Patients

ImmunityBio Survey Highlights Diverse Treatment Priorities Among Patients With BCG-Unresponsive NMIBC ImmunityBio has unveiled new patient survey findings that shed light on how individuals living with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) make treatment decisions following BCG therapy…

Read MoreImmunityBio Shares ISPOR 2026 Survey on Bladder Preservation Preference in UK NMIBC Patients

Natera Showcases 35 ASCO Studies, Strengthening Leadership in Oncology Clinical Data

Natera Showcases Expansive Oncology Research Program at ASCO 2026, Highlighting Advances in MRD Testing and Precision Cancer Care Natera announced an extensive oncology research program for the 2026 Annual Meeting of the American Society of Clinical Oncology, underscoring the company’s…

Read MoreNatera Showcases 35 ASCO Studies, Strengthening Leadership in Oncology Clinical Data

Acuitas Therapeutics Highlights In Vivo CAR T Engineering and Ionizable Lipid Quality at 2026 ASGCT Meeting

Acuitas Therapeutics Showcases In Vivo CAR T Engineering and Lipid Innovations at ASGCT 2026 Acuitas Therapeutics concluded a prominent showing at the American Society of Gene & Cell Therapy 2026 Annual Meeting with the presentation of new research focused on…

Read MoreAcuitas Therapeutics Highlights In Vivo CAR T Engineering and Ionizable Lipid Quality at 2026 ASGCT Meeting

Sensome Reports Positive First-in-Human Results for In Situ Lung Cancer Tumor Detection Technology

Sensome Reports Encouraging First-in-Human Clinical Results for Its Innovative In Situ Lung Tumor Detection Technology Sensome has announced positive results from its first-in-human INSPECT clinical study evaluating the company’s microsensor-enabled smart stylet technology for bronchoscopic lung biopsy procedures. According to…

Read MoreSensome Reports Positive First-in-Human Results for In Situ Lung Cancer Tumor Detection Technology

ForePass Demonstrates Bariatric Surgery-Like Benefits While Surpassing Leading GLP-1 Therapies

ForePass Shows Surgery-Like Benefits While Advancing a Less Invasive Approach to Obesity Treatment Keyron has announced the publication of new preclinical research in Gut, one of the world’s highest-ranked gastroenterology journals, highlighting the potential of its ForePass endoscopic metabolic bypass…

Read MoreForePass Demonstrates Bariatric Surgery-Like Benefits While Surpassing Leading GLP-1 Therapies

JCR Pharmaceuticals Showcases Promising CNS Gene Therapy Data at ASGCT 2026

JCR Pharmaceuticals Showcases Preclinical Gene Therapy Findings Demonstrating Strong CNS Uptake at the American Society of Gene and Cell Therapy 29th Annual Meeting JCR Pharmaceuticals presented new preclinical findings highlighting the potential of its proprietary JUST-AAV gene therapy platform during…

Read MoreJCR Pharmaceuticals Showcases Promising CNS Gene Therapy Data at ASGCT 2026

ImmunityBio Secures U.S. Patents for ANKTIVA-BCG Cancer Therapy Through 2035

ImmunityBio Secures U.S. Patent Protection Through 2035 for ANKTIVA-BCG Combination Cancer Therapy ImmunityBio has announced the issuance of five United States patents covering the combination of its IL-15 receptor agonist ANKTIVA with Bacillus Calmette-Guérin for the treatment of cancer, significantly…

Read MoreImmunityBio Secures U.S. Patents for ANKTIVA-BCG Cancer Therapy Through 2035

Agenus Publishes Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Liver Cancer

Agenus Publishes Promising Phase 1b Data for Botensilimab and Balstilimab Combination in Advanced Liver Cancer Agenus has announced the publication of new clinical data highlighting the potential of its investigational immunotherapy combination of botensilimab and balstilimab in patients with advanced…

Read MoreAgenus Publishes Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Liver Cancer

Bayer Launches Midol® in Motion Campaign to Promote PMS Relief Through Physical Activity

Bayer Launches Midol in Motion Campaign to Support PMS Symptom Relief Through Movement and Education Bayer has announced the launch of “Midol in Motion,” a new awareness and education campaign designed to help menstruators better understand and manage common premenstrual…

Read MoreBayer Launches Midol® in Motion Campaign to Promote PMS Relief Through Physical Activity

Affinia Therapeutics Showcases AFTX-201 Cardiomyopathy Data and AAV Platform Advances at ASGCT 2026

Affinia Therapeutics Highlights Advances in Gene Therapy Pipeline and Manufacturing at ASGCT 2026 Affinia Therapeutics showcased major progress across its cardiovascular and central nervous system gene therapy programs during multiple presentations at the 29th Annual Meeting of the American Society…

Read MoreAffinia Therapeutics Showcases AFTX-201 Cardiomyopathy Data and AAV Platform Advances at ASGCT 2026

Heart Failure 2026 Data Highlight Vutrisiran’s Strong Benefits Across ATTR-CM Patient Groups

New Heart Failure 2026 Analyses Highlight Consistent Clinical Benefits of Vutrisiran Across Diverse ATTR-CM Patient Groups Alnylam Pharmaceuticals has announced new analyses from its Phase 3 HELIOS-B clinical trial evaluating vutrisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), providing…

Read MoreHeart Failure 2026 Data Highlight Vutrisiran’s Strong Benefits Across ATTR-CM Patient Groups